Bladder Cancer Coverage from Every Angle
Editor:
Thomas Flaig, MD
Advertisement
Advertisement

Videos

Roger Li, MD, on Combining Adenovirus CG007 With Pembrolizumab in Bladder Cancer

Nicholas D. James, MB, PhD, on Bladder Cancer: MRI and Biopsy vs Resection for Cystoscopic Staging

Jonathan E. Rosenberg, MD, on Enfortumab Vedotin-ejfv vs Chemotherapy in Urothelial Cancer: Practical Clinical Considerations

Monika Joshi, MD, on Findings on Chemoradiation With Durvalumab in Urothelial Carcinoma

Sumanta K. Pal, MD: Interpreting the Latest Results From the COSMIC-021 Study on Cabozantinib Plus Atezolizumab in Urothelial Carcinoma

Thomas W. Flaig, MD, on Choosing Among Many New Bladder Cancer Treatment Options

Simon J. Crabb, PhD, MBBS, on Rucaparib Following Chemotherapy for Urothelial Carcinoma: Update From the ATLANTIS Trial

Massimo Di Maio, MD, on Niraparib and Best Supportive Care as Maintenance Therapy for Urothelial Cancer

Petros Grivas, MD, PhD, on Update on Treatment With Sacituzumab Govitecan-hziy and Pembrolizumab in Urothelial Cancer

Wesley Yip, MD, on Clinical Implications of New Findings on Neoadjuvant Chemotherapy for Urothelial Carcinoma

Jonathan E. Rosenberg, MD, on Clinical Implications of New Findings on Durvalumab Plus Olaparib for Stage IV Urothelial Cancer

Daniel P. Petrylak, MD, on Enfortumab Vedotin-ejfv as Monotherapy for Bladder Cancer

Roger Li, MD, on Bladder Cancer: A Possible New Treatment in CG0070 Plus Pembrolizumab

Thomas Powles, MD, PhD, on Clinical Implications of the NORSE Trial: Erdafitinib Plus Cetrelimab in FGFR-Altered Advanced Urothelial Carcinoma

Peter H. O’Donnell, MD, on Pembrolizumab for Cisplatin-Ineligible Patients With Advanced Urothelial Cancer

Matt D. Galsky, MD, on Predicting Which Patients With Bladder Cancer Given Neoadjuvant Therapy May Avoid Cystectomy

Sumanta K. Pal, MD: Does Adding Berzosertib to Chemotherapy Improve Outcomes in Urothelial Carcinoma?

Enrique Grande, MD, PhD, on Results From IMvigor130: Atezolizumab Plus Platinum-Based Chemotherapy for Urothelial Cancer

Arlene O. Siefker-Radtke, MD, on Comparing Immunotherapy and Antibody-Drug Conjugates for Urothelial Bladder Cancer

Tracy L. Rose, MD, on Clinical Implications of Treating Bladder Cancer With Neoadjuvant Gemcitabine, Cisplatin, and Pembrolizumab

Thomas Powles, MD, PhD, on Enfortumab Vedotin-ejfv: New Standard of Care for Aggressive Urothelial Carcinoma?

Daniel M. Geynisman, MD, on a Strategic Approach to Neoadjuvant Treatment of Bladder Cancer

Monika Joshi, MD, on After the DUART Trial: Next Steps in Treating Urothelial Cancer of the Bladder

Aristotelis Bamias, MD, PhD, on Urothelial Carcinoma: Atezolizumab and Platinum-Based Chemotherapy

Jonathan E. Rosenberg, MD, on Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Syed A. Hussain, MD, on Neoadjuvant Treatment With Nintedanib for Locally Advanced Disease

Thomas Flaig, MD, on Advances in Bladder Cancer Treatment: Expert Perspective

Thomas Flaig, MD, on NCCN Clinical Practice Guidelines in Oncology®: Their Increasing Importance in Bladder Cancer

Nicholas Vogelzang, MD, on Urothelial Cancer: Lenvatinib Plus Pembrolizumab

Daniel P. Petrylak, MD, on Urothelial Carcinoma: Results of the RANGE Trial

Petros Grivas, MD, PhD, on Urothelial Carcinoma Roundup: Expert Perspective

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on Urothelial, RCC, and Other GU Malignancies: Two Key Trials

Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.